Latest California Healthline Stories
KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discussed drug costs with Scott Simon, the host of NPR’s Weekend Edition on Saturday, Feb. 10. This is a transcript of that conversation.
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits, though their efforts fell short in California, which passed a drug transparency bill in 2017 despite massive opposition from drugmakers.
Expert Advice For The Corporate Titans Taking On Health Care
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
Facebook Live: It’s 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this Facebook Live chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
Drug Overdose Deaths Plateau In California, Soar Nationally
Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat — or even falling — in many Western states, where it has not yet overwhelmed the drug supply.
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Pharmacy Costs Continue To Soar For California’s Public Employee Health System
The increase has been largely driven by the cost of specialty drugs. The agency, which provides health coverage for 1.4 million people, will address cost containment at a meeting Tuesday and at a panel discussion in January.